JP2020517692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517692A5 JP2020517692A5 JP2019557872A JP2019557872A JP2020517692A5 JP 2020517692 A5 JP2020517692 A5 JP 2020517692A5 JP 2019557872 A JP2019557872 A JP 2019557872A JP 2019557872 A JP2019557872 A JP 2019557872A JP 2020517692 A5 JP2020517692 A5 JP 2020517692A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- item
- genetically modified
- modified
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 172
- 238000000034 method Methods 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 51
- 229940124597 therapeutic agent Drugs 0.000 claims description 51
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 13
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 claims description 8
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 102100035028 Alpha-L-iduronidase Human genes 0.000 claims description 3
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000010354 integration Effects 0.000 description 16
- 108010003381 Iduronidase Proteins 0.000 description 13
- 102000004627 Iduronidase Human genes 0.000 description 13
- 229920002683 Glycosaminoglycan Polymers 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 229960000485 methotrexate Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000035605 chemotaxis Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 101100332578 Homo sapiens DHFR gene Proteins 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 101710181613 Interleukin-31 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023072284A JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2024115656A JP2024153703A (ja) | 2017-04-27 | 2024-07-19 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491151P | 2017-04-27 | 2017-04-27 | |
| US62/491,151 | 2017-04-27 | ||
| PCT/US2018/029993 WO2018201071A1 (en) | 2017-04-27 | 2018-04-27 | B cells for in vivo delivery of therapeutic agents and dosages thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072284A Division JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517692A JP2020517692A (ja) | 2020-06-18 |
| JP2020517692A5 true JP2020517692A5 (enExample) | 2021-05-20 |
Family
ID=63919297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557872A Withdrawn JP2020517692A (ja) | 2017-04-27 | 2018-04-27 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2023072284A Active JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2024115656A Pending JP2024153703A (ja) | 2017-04-27 | 2024-07-19 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072284A Active JP7526312B2 (ja) | 2017-04-27 | 2023-04-26 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
| JP2024115656A Pending JP2024153703A (ja) | 2017-04-27 | 2024-07-19 | 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220193129A1 (enExample) |
| EP (1) | EP3615045A4 (enExample) |
| JP (3) | JP2020517692A (enExample) |
| CN (1) | CN110709090A (enExample) |
| AU (2) | AU2018256887B2 (enExample) |
| BR (1) | BR112019022473A2 (enExample) |
| CA (1) | CA3061048A1 (enExample) |
| WO (1) | WO2018201071A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12440513B2 (en) | 2019-03-22 | 2025-10-14 | Albany Medical College | Methods for improving cognitive function |
| CN110499336B (zh) * | 2019-08-23 | 2021-10-12 | 华南农业大学 | 一种利用小分子化合物提高基因组定点修饰效率的方法 |
| JP2023548118A (ja) * | 2020-10-30 | 2023-11-15 | イミュソフト コーポレーション | 治療剤のｉｎ ｖｉｖｏ送達のために、遺伝子改変Ｂ細胞を投与する方法 |
| TW202309270A (zh) * | 2021-04-19 | 2023-03-01 | 美商步行魚醫療公司 | 用於細胞療法的ｂ細胞擴增之方法 |
| WO2024044697A2 (en) * | 2022-08-24 | 2024-02-29 | Walking Fish Therapeutics, Inc. | Compositions and methods for treatment of fabry disease |
| WO2024220447A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
| AU2024257819A1 (en) * | 2023-04-17 | 2025-10-23 | Be Biopharma, Inc. | Engineered cell preparations for treatment of hemophilia |
| US20250152714A1 (en) | 2023-11-15 | 2025-05-15 | Immusoft Corporation | Migratory modified differentiated b cells for cancer therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2029165B1 (en) * | 2006-04-27 | 2014-12-03 | Cellid Co., Ltd | B cell-based vaccine loaded with the ligand of natural killer t cell and antigen |
| AU2016202625A1 (en) * | 2007-07-27 | 2016-05-19 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| WO2011085247A2 (en) * | 2010-01-08 | 2011-07-14 | Immusoft Corporation | Vectors and methods for transducing b cells |
| EP2971039B1 (en) * | 2013-03-14 | 2020-01-01 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
| EP3575312A1 (en) * | 2014-01-27 | 2019-12-04 | Molecular Templates, Inc. | De-immunized shiga toxin a subunit effector polypeptides for applications in mammals |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| WO2016187017A1 (en) * | 2015-05-15 | 2016-11-24 | Mcivor R Scott | Adeno-associated for therapeutic delivery to central nervous system |
| JP2021515576A (ja) * | 2018-03-16 | 2021-06-24 | イミュソフト コーポレーション | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
-
2018
- 2018-04-27 CN CN201880037089.5A patent/CN110709090A/zh active Pending
- 2018-04-27 US US16/607,962 patent/US20220193129A1/en active Pending
- 2018-04-27 BR BR112019022473-4A patent/BR112019022473A2/pt unknown
- 2018-04-27 EP EP18790427.1A patent/EP3615045A4/en active Pending
- 2018-04-27 CA CA3061048A patent/CA3061048A1/en active Pending
- 2018-04-27 WO PCT/US2018/029993 patent/WO2018201071A1/en not_active Ceased
- 2018-04-27 JP JP2019557872A patent/JP2020517692A/ja not_active Withdrawn
- 2018-04-27 AU AU2018256887A patent/AU2018256887B2/en active Active
-
2023
- 2023-04-26 JP JP2023072284A patent/JP7526312B2/ja active Active
-
2024
- 2024-07-19 JP JP2024115656A patent/JP2024153703A/ja active Pending
-
2025
- 2025-04-09 AU AU2025202508A patent/AU2025202508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517692A5 (enExample) | ||
| Wang et al. | Transcription factors associated with IL-15 cytokine signaling during NK cell development | |
| JP7495695B2 (ja) | 幹細胞の免疫制御作用を調節する方法 | |
| US20230203118A1 (en) | Cytokine combination | |
| CN111658670B (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
| CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
| CN102174479B (zh) | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 | |
| US12409217B2 (en) | Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties | |
| Wang et al. | Viral vectors expressing interleukin 2 for cancer immunotherapy | |
| CN107793482A (zh) | 嵌合抗原受体及其基因和重组表达载体、car133‑nkt 细胞及其制备方法和应用 | |
| JPH07503455A (ja) | 癌のリンホカイン遺伝子療法 | |
| AU2020242520B2 (en) | Method for the expansion and differentiation of T lymphocytes and NK cells in adoptive transfer therapies | |
| JP2023138660A5 (enExample) | ||
| CN106520778A (zh) | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 | |
| US20060153805A1 (en) | Viral vectors and the use of the same for gene therapy | |
| JP6687246B2 (ja) | 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用 | |
| CN117402836A (zh) | 重组溶瘤病毒及其应用 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| US20180066253A1 (en) | Methods and compositions for modifying endothelial cells | |
| US7323450B2 (en) | Complex immuno-gene medical composition for inhibiting tumor cells | |
| RU2019136194A (ru) | В-клетки для доставки терапевтических средств in vivo и их дозы | |
| JPWO2019178613A5 (enExample) | ||
| JPWO2022094284A5 (enExample) | ||
| Kerzel | L’IFN-alpha secreto da macrofagi ingegnerizzati in vivo riduce le metastasi al fegato e induce l’attivazione di processi contro regolatori che ne limitano l’efficacia | |
| CN119799717A (zh) | 核酸形式il-9联合免疫检查点药物的制剂组合与应用 |